Tolebrutinib is an oral, CNS-penetrant Bruton’s tyrosine kinase inhibitor with dual mechanism of action: peripheral B cell modulation and re-establishment of CNS microglial homeostasis. Dr Jiwon Oh (St. Michael’s Hospital, University of Toronto, Canada) joins us to discuss the phase 2b trial (NCT03889639), investigating safety and efficacy of tolebrutinib in patients with relapsing multiple sclerosis. […]